European Respiratory Journal
12/04/2019 19:05
Despite all our efforts, the disease burden of tuberculosis (TB) is not falling fast enough to reach the 2030 milestone of the End TB strategy [1]. Multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis, with low treatment success rates [1]. The repurposed drug linezolid has emerged as a core drug in MDR-TB treatment regimens [2, 3], despite its toxicity, e.g. anaemia, peripheral neuropathy and gastrointestinal disorders, optic neuritis, and thrombocytopenia [4, 5]. Currently, linezolid is used off-label, as part of Group A "Medicines to be prioritised" of the World Health Organization (WHO) MDR-TB treatment guideline [2] and in several large trials [6], such as the NIX-TB and END-TB trials.
View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.
Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.
Show or hide the record’s caption (content description).
Show actions that can be made with the search result record.
Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.